The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A single-arm confirmatory study to evaluate the efficacy of nonsurgical therapy for HER2-positive early breast cancer with clinical complete response after primary systemic therapy (JCOG1806: AMATERAS-BC study).
 
Tomomi Fujisawa
Speakers' Bureau - Chugai Pharma; Daiichi Sankyo; Novartis; Taiho Pharmaceutical
 
Tadahiko Shien
Consulting or Advisory Role - Allergan; AstraZeneca; Chugai Pharma; Daiichi Sankyo; Eisai; Kyowa Kirin; Novartis; Pfizer; Taiho Pharmaceutical; Takeda
Speakers' Bureau - Allergan; AstraZeneca; Chugai Pharma; Daiichi Sankyo; Eisai; Kyowa Kirin; Nihonkayaku; Novartis; Pfizer; Taiho Pharmaceutical; Takeda
Research Funding - Eisai (Inst); Nihonkayaku (Inst)
 
Hiroji Iwata
Honoraria - AstraZeneca; Chugai Pharma; Daiichi Sankyo; Eisai; Kyowa Hakko Kirin; Lilly Japan; Pfizer; Taiho Pharmaceutical
Consulting or Advisory Role - AstraZeneca; Chugai Pharma; Daiichi Sankyo; Kyowa Hakko Kirin; Lilly Japan; Novartis; Pfizer
Research Funding - AstraZeneca (Inst); Bayer (Inst); Boehringer Ingelheim (Inst); Chugai Pharma (Inst); Daiichi Sankyo (Inst); Kyowa Hakko Kirin (Inst); Lilly Japan (Inst); MSD (Inst); Nihonkayaku (Inst); Novartis (Inst); Pfizer (Inst); Sanofi (Inst)
 
Hideo Shigematsu
No Relationships to Disclose
 
Taro Shibata
No Relationships to Disclose
 
Keita Sasaki
No Relationships to Disclose
 
Yuko Takahashi
No Relationships to Disclose